2023Unpublished venueOpen access

Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof, Berris van Kessel, Jeroen F. van Velzen, Andries C. Bloem, Marloes E.C. Broekmans, Sonja Zweegman, Johan van Meerloo, René J.P. Musters, Pino J. Poddighe, Richard W.J. Groen, Christopher Chiu, Torben Plesner, Henk M. Lokhorst, A. Kate Sasser, Tuna Mutis, Niels W.C.J. van de Donk

Open full text 0 citations

Abstract

Daratumumab-mediated CD38 reduction of MM cells in the presence of PBMCs as shown by Western blot analysis.

About this research paper

What this paper is about

Daratumumab-mediated CD38 reduction of MM cells in the presence of PBMCs as shown by Western blot analysis.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Daratumumab-mediated CD38 reduction of MM cells in the presence of PBMCs as shown by Western blot analysis.

Key concepts: Daratumumab, CD38, Western blot, Peripheral blood mononuclear cell, Molecular biology, Multiple myeloma, Monocyte, Cancer research

Related papers

Back to paper searchBrowse research topicsOriginal source
Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab — Research Paper | ScholarLens